Skip to main content
CRBU
NASDAQ Life Sciences

Caribou Posts Q3 Loss of $26.6M, Cash Falls to $94.8M Amid Strategic Review

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.405
Mkt Cap
$44.202M
52W Low
$0.403
52W High
$2.49
52W Position info
0.5% above low
Off High info
84% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CRBU is trading near its 52-week low of $0.403 (0.5% above the low).

Summary

Caribou reported a Q3 2026 net loss of $26.6 million ($0.25 per share) and $94.8 million in cash and securities, down from $142.8 million at year-end 2025, as it runs a strategic-alternatives review after discontinuing its lead CAR-T programs.


Key Events · Earnings and Guidance · CRBU

  • Q3 Loss Narrows to $26.6M

    GAAP net loss was $26.6 million, or $0.25 per share, versus $27.5 million, or $0.30 per share, in Q3 2025.

  • Cash Drops to $94.8M

    Cash, cash equivalents, and marketable securities fell to $94.8 million at September 30, 2026 from $142.8 million at December 31, 2025 — a $48.0 million decline over nine months.

  • Spending Still Heavy Pre-Cuts

    Q3 R&D was $21.3 million and G&A $7.9 million; the October 6 workforce reduction and trial discontinuation are not yet reflected in these results.

  • Strategic Review Has No Timeline

    The board is exploring a merger, acquisition, business combination, or dissolution and liquidation, and will not update unless it approves a course of action or the review concludes.


Analysis · CRBU · Life Sciences

The cash burn Caribou is trying to stop is the story here: $94.8 million remained at September 30, down from $142.8 million at year-end 2025, against a $26.6 million quarterly loss. At the current burn rate that is roughly three and a half quarters of runway, which frames how much time the board has to land a merger, sale, or liquidation before the money runs out. The quarter itself was modestly better than a year ago — loss per share of $0.25 versus $0.30 — but the operating numbers are now secondary to the strategic-alternatives process, which the company says it will not update until the board approves a course of action.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBU was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.2M. The 52-week trading range was $0.40 to $2.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBU - Latest Insights

CRBU
Nov 05, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.405
Real-time Price: $0.3099 info
Change: -$0.0951 (-23%) info
Market Cap: $33.545M info
CRBU
Oct 06, 2026, 4:37 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.705
Real-time Price: $0.3099 info
Change: -$0.3951 (-56%) info
Market Cap: $33.545M info
CRBU
Oct 06, 2026, 4:11 PM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $1.14
Real-time Price: $0.3099 info
Change: -$0.8251 (-73%) info
Market Cap: $33.545M info
CRBU
Oct 06, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.14
Real-time Price: $0.3099 info
Change: -$0.8251 (-73%) info
Market Cap: $33.545M info
CRBU
Aug 13, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.3099 info
Change: -$1.30 (-81%) info
Market Cap: $33.545M info